Saeed Aso, Fortuna Elzbieta Nowakowska-, Jensen Gert
Institute of Medicine, Department of Molecular and Clinical Medicine/Nephrology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Clin Kidney J. 2017 Aug;10(4):496-502. doi: 10.1093/ckj/sfx052. Epub 2017 Jul 3.
To evaluate the effect of percutaneous transluminal renal angioplasty (PTRA) on split renal function (SRF) in patients with unilateral atherosclerotic renal artery stenosis (ARAS).
We performed a retrospective analysis of all consecutively examined patients at our centre with significant ARAS undergoing PTRA during 2002-07. A significant ARAS was defined as a lesion with a trans-stenotic mean arterial pressure gradient of at least 10 mmHg or a diameter stenosis >50% on angiography. Ambulatory (24 h) systolic and diastolic blood pressure (ASBP and ADBP, respectively) and calculated SRF using Tc-DTPA renal scintigraphy were evaluated before (baseline) and 4 weeks after PTRA.
ASBP and ADBP were significantly lower 4 weeks after PTRA compared with baseline levels. Although total estimated glomerular filtration rate (eGFR; four-variable Modification of Diet in Renal Disease equation) had not changed by PTRA, analysis of SRF showed significantly increased eGFR in stenotic kidneys and a comparable reduction in eGFR in non-stenotic kidneys 4 weeks after PTRA.
In patients with unilateral ARAS, PTRA significantly improved eGFR in stenotic kidneys and decreased filtration in contralateral, non-stenotic kidneys. These potentially beneficial effects may not be apparent when total renal function remains stable. The clinical significance of these findings needs to be evaluated further.
评估经皮腔内肾血管成形术(PTRA)对单侧动脉粥样硬化性肾动脉狭窄(ARAS)患者分肾功能(SRF)的影响。
我们对2002年至2007年期间在本中心连续接受检查且患有严重ARAS并接受PTRA的所有患者进行了回顾性分析。严重ARAS定义为血管造影显示跨狭窄平均动脉压梯度至少为10 mmHg或直径狭窄>50%的病变。在PTRA前(基线)和术后4周评估动态(24小时)收缩压和舒张压(分别为ASBP和ADBP),并使用Tc-DTPA肾闪烁显像计算SRF。
与基线水平相比,PTRA术后4周ASBP和ADBP显著降低。尽管经皮腔内肾血管成形术未改变总估计肾小球滤过率(eGFR;采用四变量肾脏病饮食改良方程),但对SRF的分析显示,PTRA术后4周,狭窄肾脏的eGFR显著增加,而对侧非狭窄肾脏的eGFR有类似程度的降低。
在单侧ARAS患者中,PTRA显著改善了狭窄肾脏的eGFR,并降低了对侧非狭窄肾脏的滤过率。当总肾功能保持稳定时,这些潜在的有益作用可能不明显。这些发现的临床意义需要进一步评估。